Genecia Healthcare

Genecia is a South Korean biopharmaceutical company focused on the development of regenerative cell therapies for vascular and ischemic diseases. The company leverages its proprietary stem cell technology to create treatments for conditions such as Critical Limb Ischemia (CLI) and Buerger's disease. Its lead product candidate, GNC-001, utilizes autologous bone marrow-derived mesenchymal stem cells to stimulate blood vessel formation and improve blood flow in affected limbs. Genecia's research and development efforts are centered on providing minimally invasive alternatives to surgical interventions for chronic vascular disorders. The company is actively advancing its clinical pipeline to address significant unmet needs in the field of regenerative medicine.